News

September 10, 2022

ESMO 2022: Interim Results for Treatment of Platinum-Resistant Ovarian Cancer with p62 Plasmid DNA Show Statistically Significant Changes in Progression-Free Survival

While the disease has progressed in all patients receiving standard of care, it did not progress in 40% of the patients receiving standard chemotherapy together with the experimental drug, Elenagen — and for half of the patients in the group, Elenagen has increased the time to disease progression by more than 2.5 times
May 3, 2022

CureLab Oncology Secures Patent Protection for P62 Plasmid Therapeutic in South Korea

Patent registration in South Korea opens door to commercial agreements in an enormous market with high economic potential for CureLab
April 22, 2022

University of Camerino Signs Strategic Partnership with CureLab Veterinary to Revolutionize Cancer Treatment for Companion Animals

The university is also renewing its agreement with CureLab Oncology to support its phase II clinical trials
March 30, 2022
TheScientist-Russia

The Scientist: Russian Scientists Grapple with an Uncertain Future

As the terrible Ukraine-Russia situation evolves, what does this portend for scientists located in the region? Scientists from countries with differing political systems have long collaborated with colleagues located in politically distressed and war-torn regions. Despite the associated challenges, these collaborations have combined their respective strengths and even leveraged the unique characteristics of their regional differences.
January 31, 2022

CureLab Oncology and the American Eurasian Cancer Alliance Partner to Fight Ovarian Cancer

Partnership aims to accelerate CureLab’s clinical studies by providing access to intellectual and scientific resources that can advance research and discovery in ovarian cancer prevention and treatment strategies
November 23, 2021

CureLab Oncology Secures Patent Protection in India

Patent registration in India opens door to commercial agreements in an enormous market with rising incidence of cancer
November 11, 2021

OncologyTube interviews Dr. Alex Shneider of CureLab Oncology and Prof. Sergei Krasny

Along with the OncologyTube host Stephanie Comello, Dr. Alex Shneider and Prof. Sergei Krasny discuss results from our clinical studies underway in Belarus. If you have 30 minutes, we invite you to watch the video. We’ve condensed the highlights below.
September 16, 2021

CureLab Oncology Presents at 2021 ESMO Congress

The leading professional organization for medical oncology has selected two research presentations authored by CureLab’s science team, which is currently conducting phase II clinical study of Elenagen, an experimental DNA therapy
August 11, 2021

Hormone-Resistant Prostate and Breast Cancers Added to Clinical Study Based on Encouraging Preliminary Results

Preliminary clinical results in deadly forms of breast and ovarian cancers have encouraged oncologists to expand the study to include hormone-resistant breast and metastatic prostate cancers; at the center of the study is CureLab Oncology’s Elenagen, an experimental DNA therapy
July 20, 2021

CureLab Oncology Granted US Patent for Therapeutic Use of its Lead Product in ALS, Alzheimer’s, Huntington’s, and Parkinson’s Diseases

Patent makes it feasible to commence clinical trials to establish effectiveness of its lead product and product variations for treatment of neurodegenerative diseases Patent makes it feasible to commence clinical trials to establish effectiveness of its lead product and product variations for treatment of neurodegenerative diseases
November 10, 2020
CureLab_EU

CureLab Oncology Establishes Operations in Europe

CureLab is expanding its global presence with a new office from which it will base operations in the European Union; Ricarda Cramer joins as business development director
January 22, 2021

Curelab Veterinary Launches in Animal Health Sector, Leveraging Technology Licensed from CureLab Oncology

Based on a scientifically solid proof of concept in dogs and cats, a licensed international IP portfolio, and a comprehensive scientific advisory board that includes key opinion leaders and experienced management, CureLab Veterinary intends to raise initial financing through a crowdfunding and to become profitable within 36 months of raising funds.
March 15, 2021

CureLab Oncology adds Hong Kong to expanding scope of patent protection

Patent registration in Hong Kong paves the way to establishing business operations in PRC
June 30, 2021

CureLab Oncology Submits Patent for COVID Therapeutic Ahead of Phase I Clinical Trials

CureLab Oncology intends to determine whether its Elenagen DNA vaccine can be used to reduce severity, mortality and life-threatening post-COVID complications.